Review



nmda receptor antagonist mk801  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    MedChemExpress nmda receptor antagonist mk801
    Nmda Receptor Antagonist Mk801, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 65 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nmda+receptor+antagonist+mk801/pm37130037-498-4-10?v=MedChemExpress
    Average 95 stars, based on 65 article reviews
    nmda receptor antagonist mk801 - by Bioz Stars, 2026-07
    95/100 stars

    Images



    Similar Products

    95
    MedChemExpress nmda receptor antagonist mk801
    Nmda Receptor Antagonist Mk801, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nmda+receptor+antagonist+mk801/pm37130037-498-4-10?v=MedChemExpress
    Average 95 stars, based on 1 article reviews
    nmda receptor antagonist mk801 - by Bioz Stars, 2026-07
    95/100 stars
      Buy from Supplier

    96
    Tocris non competitive nmda receptor antagonist mk801
    Non Competitive Nmda Receptor Antagonist Mk801, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nmda+receptor+antagonist+mk801/pmc12867824-71-7-14?v=Tocris
    Average 96 stars, based on 1 article reviews
    non competitive nmda receptor antagonist mk801 - by Bioz Stars, 2026-07
    96/100 stars
      Buy from Supplier

    90
    FUJIFILM nmda receptor antagonist mk801
    NMDA receptor-dependent FVP (A) VEPs in NR2A knockout mice on days 1 and 6 (contralateral eye stimulation). (B) Absence of changes in VEP peaks (day 1 vs. day 6) in NR2A knockout mice after visual stimulation ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.5775; P1: p = 0.5844; N2: p = 0.4964. (C) VEPs of wild-type mice injected with <t>MK801</t> intraperitoneally (0.5 mg/kg body weight) (day 1 vs. day 6, contralateral eye stimulation) 30 min before the start of visual stimulation. (D) Absence of FVP (day 1 vs. day 6) in MK801 treated wild type mice after visual stimulation. VEP peak N2 amplitudes ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.1305; P1: p = 0.4552, N2: p = 0.1060. (E) Impaired rapid potentiation in NR2A KO mice. Visual response (area under waveform) during the initial stimulation (0–10 pulses) vs. late stimulation (190–200 pulses) on day 1. Paired t -test, p = 0.924, 6 mice, t = 0.1002, df = 5.
    Nmda Receptor Antagonist Mk801, supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nmda+receptor+antagonist+mk801/pmc11906431-80-1-5?v=FUJIFILM
    Average 90 stars, based on 1 article reviews
    nmda receptor antagonist mk801 - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    90
    FUJIFILM nmda-type glutamate receptor antagonist mk801 (dizocilpine)
    NMDA receptor-dependent FVP (A) VEPs in NR2A knockout mice on days 1 and 6 (contralateral eye stimulation). (B) Absence of changes in VEP peaks (day 1 vs. day 6) in NR2A knockout mice after visual stimulation ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.5775; P1: p = 0.5844; N2: p = 0.4964. (C) VEPs of wild-type mice injected with <t>MK801</t> intraperitoneally (0.5 mg/kg body weight) (day 1 vs. day 6, contralateral eye stimulation) 30 min before the start of visual stimulation. (D) Absence of FVP (day 1 vs. day 6) in MK801 treated wild type mice after visual stimulation. VEP peak N2 amplitudes ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.1305; P1: p = 0.4552, N2: p = 0.1060. (E) Impaired rapid potentiation in NR2A KO mice. Visual response (area under waveform) during the initial stimulation (0–10 pulses) vs. late stimulation (190–200 pulses) on day 1. Paired t -test, p = 0.924, 6 mice, t = 0.1002, df = 5.
    Nmda Type Glutamate Receptor Antagonist Mk801 (Dizocilpine), supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nmda+receptor+antagonist+mk801/pm36891608-32-10-27?v=FUJIFILM
    Average 90 stars, based on 1 article reviews
    nmda-type glutamate receptor antagonist mk801 (dizocilpine) - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    97
    Tocris glutamate nmda receptor antagonist mk801
    NMDA receptor-dependent FVP (A) VEPs in NR2A knockout mice on days 1 and 6 (contralateral eye stimulation). (B) Absence of changes in VEP peaks (day 1 vs. day 6) in NR2A knockout mice after visual stimulation ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.5775; P1: p = 0.5844; N2: p = 0.4964. (C) VEPs of wild-type mice injected with <t>MK801</t> intraperitoneally (0.5 mg/kg body weight) (day 1 vs. day 6, contralateral eye stimulation) 30 min before the start of visual stimulation. (D) Absence of FVP (day 1 vs. day 6) in MK801 treated wild type mice after visual stimulation. VEP peak N2 amplitudes ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.1305; P1: p = 0.4552, N2: p = 0.1060. (E) Impaired rapid potentiation in NR2A KO mice. Visual response (area under waveform) during the initial stimulation (0–10 pulses) vs. late stimulation (190–200 pulses) on day 1. Paired t -test, p = 0.924, 6 mice, t = 0.1002, df = 5.
    Glutamate Nmda Receptor Antagonist Mk801, supplied by Tocris, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nmda+receptor+antagonist+mk801/pm34934000-274-16-23?v=Tocris
    Average 97 stars, based on 1 article reviews
    glutamate nmda receptor antagonist mk801 - by Bioz Stars, 2026-07
    97/100 stars
      Buy from Supplier

    97
    Tocris nmda receptor antagonist mk801
    NMDA receptor-dependent FVP (A) VEPs in NR2A knockout mice on days 1 and 6 (contralateral eye stimulation). (B) Absence of changes in VEP peaks (day 1 vs. day 6) in NR2A knockout mice after visual stimulation ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.5775; P1: p = 0.5844; N2: p = 0.4964. (C) VEPs of wild-type mice injected with <t>MK801</t> intraperitoneally (0.5 mg/kg body weight) (day 1 vs. day 6, contralateral eye stimulation) 30 min before the start of visual stimulation. (D) Absence of FVP (day 1 vs. day 6) in MK801 treated wild type mice after visual stimulation. VEP peak N2 amplitudes ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.1305; P1: p = 0.4552, N2: p = 0.1060. (E) Impaired rapid potentiation in NR2A KO mice. Visual response (area under waveform) during the initial stimulation (0–10 pulses) vs. late stimulation (190–200 pulses) on day 1. Paired t -test, p = 0.924, 6 mice, t = 0.1002, df = 5.
    Nmda Receptor Antagonist Mk801, supplied by Tocris, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nmda+receptor+antagonist+mk801/pm33596432-63-7-11?v=Tocris
    Average 97 stars, based on 1 article reviews
    nmda receptor antagonist mk801 - by Bioz Stars, 2026-07
    97/100 stars
      Buy from Supplier

    90
    Biotrend Chemicals nmda receptor antagonist mk801
    NMDA receptor-dependent FVP (A) VEPs in NR2A knockout mice on days 1 and 6 (contralateral eye stimulation). (B) Absence of changes in VEP peaks (day 1 vs. day 6) in NR2A knockout mice after visual stimulation ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.5775; P1: p = 0.5844; N2: p = 0.4964. (C) VEPs of wild-type mice injected with <t>MK801</t> intraperitoneally (0.5 mg/kg body weight) (day 1 vs. day 6, contralateral eye stimulation) 30 min before the start of visual stimulation. (D) Absence of FVP (day 1 vs. day 6) in MK801 treated wild type mice after visual stimulation. VEP peak N2 amplitudes ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.1305; P1: p = 0.4552, N2: p = 0.1060. (E) Impaired rapid potentiation in NR2A KO mice. Visual response (area under waveform) during the initial stimulation (0–10 pulses) vs. late stimulation (190–200 pulses) on day 1. Paired t -test, p = 0.924, 6 mice, t = 0.1002, df = 5.
    Nmda Receptor Antagonist Mk801, supplied by Biotrend Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nmda+receptor+antagonist+mk801/pm29438741-74-1-8?v=Biotrend+Chemicals
    Average 90 stars, based on 1 article reviews
    nmda receptor antagonist mk801 - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    95
    Tocris mk801 hydrogen maleate mk 801 non competitive nmda receptor antagonist tocris
    NMDA receptor-dependent FVP (A) VEPs in NR2A knockout mice on days 1 and 6 (contralateral eye stimulation). (B) Absence of changes in VEP peaks (day 1 vs. day 6) in NR2A knockout mice after visual stimulation ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.5775; P1: p = 0.5844; N2: p = 0.4964. (C) VEPs of wild-type mice injected with <t>MK801</t> intraperitoneally (0.5 mg/kg body weight) (day 1 vs. day 6, contralateral eye stimulation) 30 min before the start of visual stimulation. (D) Absence of FVP (day 1 vs. day 6) in MK801 treated wild type mice after visual stimulation. VEP peak N2 amplitudes ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.1305; P1: p = 0.4552, N2: p = 0.1060. (E) Impaired rapid potentiation in NR2A KO mice. Visual response (area under waveform) during the initial stimulation (0–10 pulses) vs. late stimulation (190–200 pulses) on day 1. Paired t -test, p = 0.924, 6 mice, t = 0.1002, df = 5.
    Mk801 Hydrogen Maleate Mk 801 Non Competitive Nmda Receptor Antagonist Tocris, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nmda+receptor+antagonist+mk801/pm28153530-61-26-34?v=Tocris
    Average 95 stars, based on 1 article reviews
    mk801 hydrogen maleate mk 801 non competitive nmda receptor antagonist tocris - by Bioz Stars, 2026-07
    95/100 stars
      Buy from Supplier

    Image Search Results


    NMDA receptor-dependent FVP (A) VEPs in NR2A knockout mice on days 1 and 6 (contralateral eye stimulation). (B) Absence of changes in VEP peaks (day 1 vs. day 6) in NR2A knockout mice after visual stimulation ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.5775; P1: p = 0.5844; N2: p = 0.4964. (C) VEPs of wild-type mice injected with MK801 intraperitoneally (0.5 mg/kg body weight) (day 1 vs. day 6, contralateral eye stimulation) 30 min before the start of visual stimulation. (D) Absence of FVP (day 1 vs. day 6) in MK801 treated wild type mice after visual stimulation. VEP peak N2 amplitudes ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.1305; P1: p = 0.4552, N2: p = 0.1060. (E) Impaired rapid potentiation in NR2A KO mice. Visual response (area under waveform) during the initial stimulation (0–10 pulses) vs. late stimulation (190–200 pulses) on day 1. Paired t -test, p = 0.924, 6 mice, t = 0.1002, df = 5.

    Journal: Frontiers in Neural Circuits

    Article Title: Rapid and cumulative adult plasticity in the mouse visual cortex

    doi: 10.3389/fncir.2025.1537305

    Figure Lengend Snippet: NMDA receptor-dependent FVP (A) VEPs in NR2A knockout mice on days 1 and 6 (contralateral eye stimulation). (B) Absence of changes in VEP peaks (day 1 vs. day 6) in NR2A knockout mice after visual stimulation ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.5775; P1: p = 0.5844; N2: p = 0.4964. (C) VEPs of wild-type mice injected with MK801 intraperitoneally (0.5 mg/kg body weight) (day 1 vs. day 6, contralateral eye stimulation) 30 min before the start of visual stimulation. (D) Absence of FVP (day 1 vs. day 6) in MK801 treated wild type mice after visual stimulation. VEP peak N2 amplitudes ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.1305; P1: p = 0.4552, N2: p = 0.1060. (E) Impaired rapid potentiation in NR2A KO mice. Visual response (area under waveform) during the initial stimulation (0–10 pulses) vs. late stimulation (190–200 pulses) on day 1. Paired t -test, p = 0.924, 6 mice, t = 0.1002, df = 5.

    Article Snippet: The NMDA receptor antagonist MK801 (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) was dissolved in saline (0.1 mg/mL) and administered intraperitoneally (0.5 mg/kg) 15 min before daily recording sessions for 6 consecutive days.

    Techniques: Knock-Out, MANN-WHITNEY, Injection